TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02813135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadraciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadraciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Study: NCT02203565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT00268346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: ZD1839 treatment will be taken once a day PO, every day about the same time
Study: NCT03154658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.35%
Description: The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study: NCT03154658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.35%
Description: The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
Study: NCT00449072

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
Study: NCT01116440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
Study: NCT02261545

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 Fatty Acid
Description: n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
Study: NCT00449072

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
Study: NCT04077463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study: NCT04077463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an intravenous (IV) infusion.
Study: NCT00449072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAA-AQ, Nasacort® AQ
Description: 110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Claritin®
Description: Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
Study: NCT04077463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as IV infusion.
Study: NCT00581373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 16 fl oz
Description: water 16 fl oz in AM and repeat in late afternoon
Study: NCT02261545

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
Study: NCT00449072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Claritin®
Description: Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
Study: NCT04525807

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-omics
Description: Use multi-omics to analyze
Study: NCT02514174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: afatinib starting at 30 mg daily dose
Study: NCT02202174

Intervention type: DEVICE
Intervention: Supraglottic Airway Device
Study: NCT03696225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Description: Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
Study: NCT03299153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: barberry juice
Study: NCT02229890

Intervention type: DRUG
Intervention: alteplase
Study: NCT04644133

Intervention type: OTHER
Intervention: Paper diary
Description: Subjects will be asked to complete a 2 week paper stool diary.

Intervention type: OTHER
Intervention: Paper diary
Description: Subjects will be asked to complete a 2 week paper stool diary.

Intervention type: OTHER
Intervention: Paper diary
Description: Subjects will be asked to complete a 2 week paper stool diary.

Intervention type: OTHER
Intervention: Electronic APP diary
Description: Subjects will be asked to complete a 2 week paper stool diary.

Intervention type: OTHER
Intervention: Electronic APP diary
Description: Subjects will be asked to complete a 2 week paper stool diary.

Intervention type: OTHER
Intervention: Electronic APP diary
Description: Subjects will be asked to complete a 2 week paper stool diary.
Study: NCT02946099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc files in reciprocating motion
Description: An endodontic file that works through a reciprocating motion
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study: NCT02946099

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ProTaper Next files in continuous rotary motion
Description: An endodontic file that works through a continuous rotary motion
Study: NCT00558220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunotherapy
Description: Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses
Study: NCT04546399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study: NCT03609346

Intervention type: DEVICE
Intervention: PCI
Description: The placement of 1 or more stents in the diseased coronary artery lesion(s).
Study: NCT04546399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study: NCT00558220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction treatment part 1
Description: cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given.
Study: NCT04546399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study: NCT04309474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elezanumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV
Study: NCT01693783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03170648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture has been studied in clinical trials in cancer patients and has been shown to be helpful for management of pain, nerve damage from chemotherapy, and nausea
Study: NCT01073436

Intervention type: OTHER
Intervention: Discontinuation of therapy
Description: Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
Study: NCT00266409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niravam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niravam
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV
Study: NCT02655601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-001
Description: BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV
Study: NCT00266409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI
Description: Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI
Description: Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI
Description: Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV
Study: NCT02655601

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy.
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, and IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02655601

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Initially, temozolomide (TMZ) will be dosed at 75 mg/m2 orally daily for 42 days. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles.
Study: NCT04546399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02655601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Initially, temozolomide (TMZ) will be dosed at 75 mg/m2 orally daily for 42 days. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles.
Study: NCT04546399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcrisantaspase
Description: Given IM or IV
Study: NCT00558220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction treatment part 2 with PBPC collection
Description: Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are \>20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction treatment part 3
Description: Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart.
Study: NCT04546399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcrisantaspase
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV push or via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV push or via infusion
Study: NCT04423952

Intervention type: OTHER
Intervention: COMQ-12 questionnaire
Description: Subjects respond to COMQ-12 questionnaire twice at 15 days apart. COMQ-12 : quality of life measurement questionnaire related to chronic otitis media.

Intervention type: OTHER
Intervention: COMQ-12 questionnaire
Description: Subjects respond to COMQ-12 questionnaire twice at 15 days apart. COMQ-12 : quality of life measurement questionnaire related to chronic otitis media.
Study: NCT02778074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet cognitive behavioural therapy
Description: A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Moderated Discussion Forum
Description: Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.